Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MSON's Cash to Debt is ranked higher than
84% of the 397 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. MSON: No Debt )
MSON' s 10-Year Cash to Debt Range
Min: 0.22   Max: No Debt
Current: No Debt

Equity to Asset 0.84
MSON's Equity to Asset is ranked higher than
89% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MSON: 0.84 )
MSON' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.89
Current: 0.84

0.5
0.89
Interest Coverage No Debt
MSON's Interest Coverage is ranked higher than
82% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. MSON: No Debt )
MSON' s 10-Year Interest Coverage Range
Min: 2.41   Max: 9999.99
Current: No Debt

2.41
9999.99
F-Score: 7
Z-Score: 16.97
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -14.94
MSON's Operating margin (%) is ranked higher than
55% of the 387 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. MSON: -14.94 )
MSON' s 10-Year Operating margin (%) Range
Min: -35.87   Max: 23.51
Current: -14.94

-35.87
23.51
Net-margin (%) 8.16
MSON's Net-margin (%) is ranked higher than
82% of the 387 Companies
in the Global Medical Devices industry.

( Industry Median: 5.13 vs. MSON: 8.16 )
MSON' s 10-Year Net-margin (%) Range
Min: -28.56   Max: 19.78
Current: 8.16

-28.56
19.78
ROE (%) 9.71
MSON's ROE (%) is ranked higher than
80% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 5.61 vs. MSON: 9.71 )
MSON' s 10-Year ROE (%) Range
Min: -21.42   Max: 31.93
Current: 9.71

-21.42
31.93
ROA (%) 8.09
MSON's ROA (%) is ranked higher than
85% of the 397 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. MSON: 8.09 )
MSON' s 10-Year ROA (%) Range
Min: -18.21   Max: 24.04
Current: 8.09

-18.21
24.04
ROC (Joel Greenblatt) (%) -41.98
MSON's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 396 Companies
in the Global Medical Devices industry.

( Industry Median: 11.81 vs. MSON: -41.98 )
MSON' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -91.78   Max: 50.2
Current: -41.98

-91.78
50.2
Revenue Growth (%) 8.80
MSON's Revenue Growth (%) is ranked higher than
72% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. MSON: 8.80 )
MSON' s 10-Year Revenue Growth (%) Range
Min: -35.2   Max: 36.3
Current: 8.8

-35.2
36.3
» MSON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MSON Guru Trades in Q3 2013

Jim Simons 116,800 sh (+2.01%)
» More
Q4 2013

MSON Guru Trades in Q4 2013

Jim Simons 117,800 sh (+0.86%)
» More
Q1 2014

MSON Guru Trades in Q1 2014

Jim Simons 114,400 sh (-2.89%)
» More
Q2 2014

MSON Guru Trades in Q2 2014

Jim Simons 116,100 sh (+1.49%)
» More
» Details

Insider Trades

Latest Guru Trades with MSON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 70.20
MSON's P/E(ttm) is ranked higher than
60% of the 419 Companies
in the Global Medical Devices industry.

( Industry Median: 64.90 vs. MSON: 70.20 )
MSON' s 10-Year P/E(ttm) Range
Min: 5.18   Max: 303
Current: 70.2

5.18
303
P/B 4.96
MSON's P/B is ranked higher than
63% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. MSON: 4.96 )
MSON' s 10-Year P/B Range
Min: 0.26   Max: 5.05
Current: 4.96

0.26
5.05
P/S 5.12
MSON's P/S is ranked higher than
63% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. MSON: 5.12 )
MSON' s 10-Year P/S Range
Min: 0.12   Max: 5.21
Current: 5.12

0.12
5.21
PFCF 279.00
MSON's PFCF is ranked higher than
72% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MSON: 279.00 )
MSON' s 10-Year PFCF Range
Min: 6.46   Max: 462
Current: 279

6.46
462
EV-to-EBIT -30.35
MSON's EV-to-EBIT is ranked higher than
64% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 45.27 vs. MSON: -30.35 )
MSON' s 10-Year EV-to-EBIT Range
Min: 14.2   Max: 116.6
Current: -30.35

14.2
116.6
Current Ratio 4.95
MSON's Current Ratio is ranked higher than
87% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. MSON: 4.95 )
MSON' s 10-Year Current Ratio Range
Min: 1.55   Max: 8
Current: 4.95

1.55
8
Quick Ratio 3.59
MSON's Quick Ratio is ranked higher than
83% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. MSON: 3.59 )
MSON' s 10-Year Quick Ratio Range
Min: 0.76   Max: 6.69
Current: 3.59

0.76
6.69

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 1.50
MSON's Earnings Yield (Greenblatt) is ranked higher than
57% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. MSON: 1.50 )
MSON' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 7.1
Current: 1.5

0.9
7.1
Forward Rate of Return (Yacktman) -2.02
MSON's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.32 vs. MSON: -2.02 )
MSON' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.6   Max: 1.6
Current: -2.02

0.6
1.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:MX9.Germany
Misonix, Inc. is incorporated in the state of New York which, through its predecessors, was first organized in 1959. The Company designs, manufactures, markets and develops minimally invasive ultrasonic medical device products. The Company also develops and markets ductless fume enclosures for filtration of gaseous contaminates in the laboratory and forensic markets. Earlier the Company operates in two business segments which were organized by product types: laboratory and scientific products and medical devices. Laboratory and scientific products include the Sonicator ultrasonic liquid processor, Aura ductless fume enclosure, the Labcaire Autoscope and Guardian endoscope disinfectant systems. Medical devices include the Auto Sonix ultrasonic cutting and coagulatory system, refurbishing revenues of high-performance ultrasound systems and replacement transducers for the medical diagnostic ultrasound industry, ultrasonic lithotriptor, ultrasonic neuroaspirator and soft tissue aspirator. The Company's operations outside the United States consist of a 100% ownership in Labcaire Systems, Ltd. This business consists of designing, manufacturing, servicing and marketing the ISIS and Guardian endoscope disinfection systems and air-handling systems for the protection of personnel, products and the environment from airborne hazards. The Company also has a 60% ownership in UKHIFU Limited, which is the sales/marketing and service arm of the Company for the ablation of prostate cancer in the United Kingdom. The Company has a 100% ownership in Misonix, Ltd. On October 19, 2011, Misonix sold its Laboratory and Forensic Safety Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. The Company's 95% owned subsidiary, Acoustic Marketing Research, Inc. doing business as Sonora Medical Systems, located in Longmont, Colorado, is an ISO 9001 certified depot level repair facility for MRI and diagnostic ultrasound subsystems, as well as a factory level repair center for diagnostic ultrasound transducers. In addition, Sonora manufactures test equipment to appropriately diagnose failures with ultrasound systems and probes and to establish baseline performance and maintain quality assurance programs for ultrasound systems. The Company's 100% owned subsidiary, Hearing Innovations, Inc., is a development company with patented HiSonic ultrasonic technology for the treatment of profound deafness and tinnitus. The Company relies on its licensee, USS, for marketing its ultrasonic Auto Sonix surgical device. The Company relies on distributors such as Mentor Corporation, Aesculap, Inc. and independent distributors for the marketing of its other medical products. The Company sells its SonicOne(r) Wound Debridement System and the Ultrasonic BoneScalpel(tm) for certain applications through direct sales persons throughout the United States and through distributors outside the United States. The Company
» More Articles for MSON

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight May 19 2013 
comment on MSON Mar 06 2013 
MISONIX Inc. (MSON) CEO Michael A Jr Mcmanus buys 5,000 Shares Dec 01 2009 
MISONIX Inc. Reports Operating Results (10-Q) Nov 16 2009 
MISONIX Inc. Reports Operating Results (10-K) Sep 28 2009 
FirstEnergy Files Application To Consolidate Transmission Assets Into PJM Aug 17 2009 
Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million Aug 05 2009 
MISONIX Inc. Reports Operating Results (10-Q) May 12 2009 
Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008 Feb 09 2009 
Misonix Announces New HIFU Distribution Agreement for Italy Jan 05 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Sep 19 2014
MISONIX INC Files SEC form 10-K, Annual Report Sep 17 2014
MISONIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Sep 11 2014
Misonix Inc Earnings Call scheduled for 4:30 pm ET today Sep 10 2014
Misonix, Inc. Announces Fourth Quarter and Fiscal Year End 2014 Financial Results Sep 10 2014
Q4 2014 Misonix Earnings Release - After Market Close Sep 10 2014
Misonix, Inc. To Report Fourth Quarter and Fiscal Year 2014 Financial Results On Wednesday,... Sep 05 2014
Misonix, Inc. Enhances its Digital Presence with the Unveiling of its New BoneScalpel™ App Jul 24 2014
Misonix Hosts Hands-on Workshop on Ultrasonic Bone Surgery Jul 17 2014
Misonix To Showcase Ultrasonic BoneScalpel™ at the International Meeting on Advanced Spine... Jul 16 2014
Misonix BoneScalpel™ Reported to Save Blood Loss in Spinal Fusions with Similar Diagnosis Jul 15 2014
MISONIX INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jul 01 2014
Ultrasonic BoneScalpel™ Making Spine Surgery Safe and Efficient Jun 04 2014
MISONIX INC Financials May 16 2014
MISONIX INC Files SEC form 8-K, Results of Operations and Financial Condition May 09 2014
Misonix reports Q3 EPS 5c, one estimate 2c May 08 2014
MISONIX INC Files SEC form 10-Q, Quarterly Report May 08 2014
Misonix, Inc. Announces Third Quarter Fiscal Year 2014 Financial Results May 08 2014
Misonix, Inc. To Report Third Quarter 2014 Financial Results On Thursday, May 8, 2014 May 02 2014
Misonix Showcases BoneScalpel™ And SonaStar® For A Worldwide Audience At The 82nd American... Apr 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK